Gavin J. Kilpatrick

Gavin J. Kilpatrick

Auto-generated profile, based on publicly available information

Gavin J. Kilpatrick

University of Hertfordshire

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1987 in Nature
Verified
Journal Article
Closed access
GKG. J. Kilpatrick
G. J. Kilpatrick
BJB. J. Jones
B. J. Jones
MTM. B. Tyers
M. B. Tyers

1 July 2007 in Anesthesiology
Verified
Journal Article
Open access
PDF file
GKGavin J. Kilpatrick
Gavin J. Kilpatrick
MMMargaret S. McIntyre
Margaret S. McIntyre
RCRichard F. Cox
Richard F. Cox
JSJeffrey A. Stafford
Jeffrey A. Stafford
GPGregory J. Pacofsky
Gregory J. Pacofsky
GTGary S. Tilbrook
Gary S. Tilbrook
Background: A new benzodiazepine derivative, CNS 7056, has been developed to permit a superior sedative profile to current agents, i.e., more predictable fast onset, short duration of sedative action, and rapid recovery profile. This goal has been achieved by rendering the compound susceptible to metabolism via esterases. The authors now report on the profile of CNS 7056 in vitro and in vivo. Methods: The affinity of CNS 7056 and its carboxylic acid metabolite, CNS 7054, for benzodiazepine receptors and their selectivity profiles were evaluated using radioligand binding. The activity of CNS 7056 and midazolam at subtypes (α1β2γ2, α2β2γ2, α3β2γ2, α5β2γ2) of the γ-aminobutyric acid type A (GABAA) receptor was evaluated using the whole cell patch clamp technique. The activity of CNS 7056 at brain benzodiazepine receptors in vivo was measured in rats using extracellular electrophysiology in the substantia nigra pars reticulata. The sedative profile was measured in rodents using the loss of righting reflex test. Results: CNS 7056 bound to brain benzodiazepine sites with high affinity. The carboxylic acid metabolite, CNS 7054, showed around 300 times lower affinity. CNS 7056 and CNS 7054 (10 μm) showed no affinity for a range of other receptors. CNS 7056 enhanced GABA currents in cells stably transfected with subtypes of the GABAA receptor. CNS 7056, like midazolam and other classic benzodiazepines, did not show clear selectivity between subtypes of the GABAA receptor. CNS 7056 (intravenous) caused a dose-dependent inhibition of substantia nigra pars reticulata neuronal firing and recovery to baseline firing rates was reached rapidly. CNS 7056 (intravenous) induced loss of the righting reflex in rodents. The duration of loss of righting reflex was short (< 10 min) and was inhibited by pretreatment with flumazenil. Conclusions: CNS 7065 is a high-affinity and selective ligand for the benzodiazepine site on the GABAA receptor. CNS 7056 does not show selectivity between GABAA receptor subtypes. CNS 7056 is a potent sedative in rodents with a short duration of action. Inhibition of substantia nigra pars reticulata firing and the inhibition of the effects of CNS 7056 by flumazenil show that it acts at the brain benzodiazepine receptor.

1 August 2012 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
LALaurie J. Antonik
Laurie J. Antonik
DGD. Ronald Goldwater
D. Ronald Goldwater
GKGavin J. Kilpatrick
Gavin J. Kilpatrick
GTGary S. Tilbrook
Gary S. Tilbrook
KBKeith M. Borkett
Keith M. Borkett
BACKGROUND: A new benzodiazepine, remimazolam, metabolized by tissue esterases to an inactive compound, CNS 7054, has been developed to permit a fast onset, a short and more predictable duration of sedative action, and a more rapid recovery profile than with currently available benzodiazepines. We report on the safety and efficacy of the first human study. METHODS: A phase I, single-center, double-blind, placebo- and active-controlled, randomized, single-dose escalation study was conducted. Up to 10 cohorts of healthy subjects were scheduled to receive a single 1-minute IV infusion of remimazolam, midazolam, or placebo. In the 10 possible cohorts, remimazolam doses were from 0.01 to 0.35 mg/kg. In cohorts 1 to 3, 6 subjects received remimazolam and 1 placebo. From cohort 4 onward, an additional 3 subjects in each cohort received midazolam (0.075 mg/kg). Safety, pharmacokinetics, and pharmacodynamics were measured. A stop criterion of loss of consciousness for >5 minutes in >50% of subjects was predefined. RESULTS: The stop criterion was reached in cohort 9 (0.30 mg/kg remimazolam) so that 81 subjects were enrolled. Remimazolam was well tolerated in all dose cohorts, and no serious adverse events (AEs) were reported. Three AEs of mild (SpO2 85%–88%) hemoglobin desaturation (2 in the remimazolam groups and 1 in the midazolam group) resolved spontaneously, and 1 AE of moderate hemoglobin desaturation (SpO2 75%) resolved with a chin lift in the highest remimazolam dose group. No supplemental oxygen or manual ventilation was required. Vital signs remained stable throughout, although there was an increase in heart rate 2 minutes postdose for both remimazolam and midazolam. There were no reports of hypo- or hypertension. The pharmacokinetic behavior of remimazolam was linear and its systemic clearance approximately 3 times that of midazolam. Clearance was essentially independent of body weight. A rapid onset and dose-dependent sedation was observed after administration of remimazolam at 0.05 mg/kg and higher. Remimazolam (0.075 to 0.20 mg/kg) induced peak sedation levels similar to or higher than those achieved with midazolam (0.075 mg/kg). Median recovery times after approximately equieffective doses of remimazolam (0.10 and 0.15 mg/kg) and midazolam (0.075 mg/kg) were 10 and 40 minutes, respectively. CONCLUSIONS: Remimazolam provided sedation with rapid onset and offset, and was well tolerated. There was no supplemental oxygen or ventilation required. On the basis of these data, further studies on the potential utility of remimazolam for sedation/anesthesia are warranted.

23 December 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FJFrancois Jenck
Francois Jenck
JMJean-Luc Moreau
Jean-Luc Moreau
JMJames R. Martin
James R. Martin
GKGavin J. Kilpatrick
Gavin J. Kilpatrick
RRRainer K. Reinscheid
Rainer K. Reinscheid
OCOlivier Civelli
Olivier Civelli
Orphanin FQ (OFQ, Nociceptin) is a recently discovered 17-amino acid neuropeptide that is structurally related to the opioid peptides but does not bind opioid receptors. OFQ has been proposed to act as an anti-opioid peptide, but its widespread sites of action in the brain suggest that it may have more general functions. Here we show that OFQ plays an important role in higher brain functions because it can act as an anxiolytic to attenuate the behavioral inhibition of animals acutely exposed to stressful/anxiogenic environmental conditions. OFQ anxiolytic-like effects were consistent across several behavioral paradigms generating different types of anxiety states in animals (light-dark preference, elevated plus-maze, exploratory behavior of an unfamiliar environment, pharmacological anxiogenesis, operant conflict) and were observed at low nonsedating doses (0.1–3 nmol, intracerebroventricular). Like conventional anxiolytics, OFQ interfered with regular sensorimotor function at high doses (>3 nmol). Our results show that an important role of OFQ is to act as an endogenous regulator of acute anxiety responses. OFQ, probably in concert with other major neuropeptides, exerts a modulatory role on the central integration of stressful stimuli and, thereby, may modulate anxiety states generated by acute stress.

1 September 1984 in Neuroscience Letters
Verified
Journal Article
Closed access
PJPeter Jenner
Peter Jenner
NRNadia M.J. Rupniak
Nadia M.J. Rupniak
SRSarah Rose
Sarah Rose
EKEamonn Kelly
Eamonn Kelly
GKGavin Kilpatrick
Gavin Kilpatrick
CMC.DAvid Marsden
C.DAvid Marsden

19 July 1993 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
CGC.J. Grossman
C.J. Grossman
GKG.J. Kilpatrick
G.J. Kilpatrick
KBK.T. Bunce
K.T. Bunce
The 5‐HT4 receptor antagonist, GR113808, has been radiolabelled to a high specific activity with tritium. Characterization of specific [3H]‐GR113808 binding in homogenates of guinea‐pig striatum and hippocampus revealed a single site of high affinity (Kd values 0.20 and 0.13 nm respectively). [3H]‐GR113808 binding was reversible and displayed rapid kinetics such that association and dissociation were complete within 3 min. Specific [3H]‐GR113808 binding was potently and stereoselectively inhibited by agonists and antagonists acting at the 5‐HT4 receptor but not by compounds selective for other 5‐HT receptors or other neurotransmitter receptors. Autoradiographic analysis revealed a discrete localization in both guinea‐pig and rat brain with high concentrations of binding in brain areas such as the striatum, substantia nigra and olfactory tubercle. [3H]‐GR113808 binding to homogenates of guinea‐pig striatum meets the criteria for labelling of the 5‐HT4 receptor and, as such, represents the first characterization of this receptor in a radioligand binding assay.